Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $99.00 by Analysts at Deutsche Bank Aktiengesellschaft

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective cut by Deutsche Bank Aktiengesellschaft from $124.00 to $99.00 in a report issued on Wednesday,Benzinga reports. They currently have a hold rating on the biotechnology company’s stock.

Several other brokerages also recently commented on SRPT. Cantor Fitzgerald reissued an “overweight” rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday. Piper Sandler lowered their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Royal Bank of Canada lowered their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Finally, Scotiabank began coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They set a “sector perform” rating and a $105.00 target price for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $168.55.

Sarepta Therapeutics Stock Up 8.7 %

Shares of NASDAQ SRPT opened at $79.97 on Wednesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $7.76 billion, a price-to-earnings ratio of 63.98 and a beta of 0.79. Sarepta Therapeutics has a 12 month low of $73.06 and a 12 month high of $173.25. The stock has a 50-day moving average price of $109.26 and a two-hundred day moving average price of $118.86.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after buying an additional 12,000 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $3,829,000. Summit Partners Public Asset Management LLC raised its position in shares of Sarepta Therapeutics by 547.9% during the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares during the period. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.